Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematopoietic and Lymphatic System Neoplasm 1Graft vs Host Disease 1Cholangiocarcinoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

pembrolizumab 47Carboplatin 35Paclitaxel 28Specimen Handling 20Cyclophosphamide 17Capecitabine 16Magnetic Resonance Spectroscopy 15sacituzumab govitecan 13Gemcitabine 13Biopsy 13Taxes 12130-nm albumin-bound paclitaxel 11Albumin-Bound Paclitaxel 9olaparib 8Doxorubicin 8Nivolumab 7fludarabine 6Cisplatin 6eribulin 5atezolizumab 5Radiotherapy 5Docetaxel 5durvalumab 4Immunoglobulin G 4Fulvestrant 4Epirubicin 4Drug Therapy 4Bevacizumab 4veliparib 3toripalimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × axatilimab × 90 days × Clear all
NCT05491226 2026-04-20

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Cedars-Sinai Medical Center

Phase 2 Recruiting
35 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07015853 2026-04-20

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Cedars-Sinai Medical Center

Phase 2 Not yet recruiting
34 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡